Literature DB >> 31144467

A Chinese practice guideline of the assisted reproductive technology strategies for women with advanced age.

Li Jiang1, Yaolong Chen2,3,4, Qi Wang5,6, Xiaoqin Wang2,3,4, Xufei Luo2,3,4, Junqiao Chen7, Hongjing Han1, Yingpu Sun8, Huan Shen1.   

Abstract

More women postpone childbearing nowadays while female fertility begins to decline with advancing age. Furthermore, with the rolling out of the two-child policy, there is a huge demand for a second child for Chinese aged women. There are various assisted reproductive technology (ART) strategies applied for age-related infertility without solid evidence. On behalf of the Society of Reproductive Medicine, Chinese Medical Association, we would like to develop a Chinese guideline of ART strategies for age-related infertility. This guideline was produced following the recommendations for standard guidelines described in the 2012 WHO Handbook for guideline development. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework was also followed. A protocol was formulated and a Guideline Development Group was formed with specialists of reproductive medicine, methodologists from Chinese GRADE working group, and patient representative. Questions regarding the ART strategies for aged infertility were formulated and 8 most important ones were chosen to be structured in PICO format (Population, Intervention, Comparison, Outcomes). Comprehensive search and review of the literature were performed and the quality of the evidence was assessed and rated based on certain criteria and be categorized as high, moderate, low, or very low. Twenty-five recommendations were formulated among members of the Guidelines Development Group (Delphi method) basing on the overall quality of the evidence, in addition to the balance between benefits and harms, values and preferences, and resource implications. The final recommendations were agreed on by consensus during face-to-face meetings. This is the first Chinese practice guideline in reproductive medicine developed following the standard and scientific method.
© 2019 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  advanced maternal age; assisted reproductive technology; evidence-based clinical practice guideline; infertility

Mesh:

Year:  2019        PMID: 31144467     DOI: 10.1111/jebm.12346

Source DB:  PubMed          Journal:  J Evid Based Med        ISSN: 1756-5391


  5 in total

1.  Erzhi Tiangui Granules Improve In Vitro Fertilization Outcomes in Infertile Women with Advanced Age.

Authors:  Jinlong Sun; Jing-Yan Song; Yao Dong; Shan Xiang; Qiong Guo
Journal:  Evid Based Complement Alternat Med       Date:  2021-08-12       Impact factor: 2.629

2.  Successful pregnancy in a woman with bilateral fallopian tube obstruction and diminished ovarian reserve treated with electroacupuncture: A case report.

Authors:  Biyun Sun; Zhishun Liu
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

3.  Human amnion-derived mesenchymal stem cells improved the reproductive function of age-related diminished ovarian reserve in mice through Ampk/FoxO3a signaling pathway.

Authors:  Hanwen Liu; Chunyan Jiang; Boya La; Meng Cao; Song Ning; Jing Zhou; Zhengjie Yan; Chuyu Li; Yugui Cui; Xiang Ma; Meilian Wang; Li Chen; Youjia Yu; Feng Chen; Yuexin Zhang; Huimin Wu; Jiayin Liu; Lianju Qin
Journal:  Stem Cell Res Ther       Date:  2021-06-02       Impact factor: 6.832

4.  Promoting breastfeeding in Chinese women undergoing cesarean section based on the health belief model: A randomized controlled trial.

Authors:  Lei Hu; Tingting Ding; Juan Hu; Biru Luo
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

5.  How does the two-child policy affect the sex ratio at birth in China? A cross-sectional study.

Authors:  S L Fan; C N Xiao; Y K Zhang; Y L Li; X L Wang; L Wang
Journal:  BMC Public Health       Date:  2020-05-27       Impact factor: 3.295

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.